Weijing Sun - Concepedia

Author

Weijing Sun

Also Known As

Joaquina Baranda, Rashna Madan, W J Sun, W Sun, W. Sun, WEIJING SUN, Wei-Jing Sun, Wei-jing Sun, Weijing SUN, Weijing Sun

364

Publications

14K

Citations

H-Index

111

Concepts

All Affiliations

University of Pennsylvania University of Kansas Medical Center University of Pittsburgh UPMC Hillman Cancer Center The University of Kansas Cancer Center

About

Weijing Sun is an author at University of Pennsylvania specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	42	3.9K
2	Health Sciences	12	12	667
3	Public Health	2	2	205
4	Education	1	1	15
5	Social Sciences	1	1	45

Weijing Sun

Publications

9.8K

Citations

H-Index

Page 1

	Year	Citations
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans Gregory L. Beatty, E. Gabriela Chiorean, Matthew P. Fishman, Science	2011	1.6K
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang, The Lancet Pembrolizumab Versus PaclitaxelGastrointestinal OncologyMedicineGastroenterologySurgery	2018	1.3K
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma Eileen M. O’Reilly, Do‐Youn Oh, Neesha C. Dhani, JAMA Oncology	2019	722
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma Gregory L. Beatty, Drew A. Torigian, E. Gabriela Chiorean, Clinical Cancer Research	2013	443
Phase II/III Study of Doxorubicin With Fluorouracil Compared With Streptozocin With Fluorouracil or Dacarbazine in the Treatment of Advanced Carcinoid Tumors: Eastern Cooperative Oncology Group Study E1281 Weijing Sun, Stuart R. Lipsitz, Paul J. Catalano, Journal of Clinical Oncology	2005	355
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial Richard S. Finn, Philippe Merle, Alessandro Granito, Journal of Hepatology Additional AnalysesOncologyMedicineClinical TrialsSequential Treatment	2018	350
Sodium channel mutations in paramyotonia congenita uncouple inactivation from activation Mohamed Chahine, Alfred L. George, Ming Zhou, Neuron	1994	343
Phase I Trial of the Antivascular Agent Combretastatin A4 Phosphate on a 5-Day Schedule to Patients With Cancer: Magnetic Resonance Imaging Evidence for Altered Tumor Blood Flow James Stevenson, Mark Rosen, Weijing Sun, Journal of Clinical Oncology	2003	292
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma Ghassan K. Abou‐Alfa, Shukui Qin, Baek‐Yeol Ryoo, Annals of Oncology OncologyHepatologyCancer ManagementPhase IiiSurgery	2018	243
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome Kirti Shetty, Kate A. Timmins, Colleen Brensinger, Liver Transplantation Surgical OncologySolid Organ TransplantationAppropriate Patient SelectionPathologyPresent Selection Criteria	2004	218

Page 1